NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Th...(gthens biologics platform for robust gro...)

-- Provides opportunity for additional revenue per procedure of $2,000 to

$3,000;

-- Complements current Formagraft(R) biologic product line;

-- Allows for participation in all segments of the $1.5 billion U.S.

biologics market;

-- Leverages current market adoption of an established biologic used in

over 15,000 procedures to date; and

-- Includes rights to acquire next generation cultured version of product.

Osteocel is the only viable bone matrix product on the market that provides the three beneficial properties similar to autograft: osteoconduction (provides a scaffold for bone growth), osteoinduction (bone formation stimulation) and osteogenesis (production bone). Osteocel allows surgeons to offer the benefits of these properties to patients without the discomfort and potential complications of autograft harvesting, in addition to eliminating the time spent on a secondary surgical procedure. Osteocel is produced for use in spinal applications through a proprietary processing method that preserves the native stem cell population that resides in marrow rich bone.

The three main components that comprise Osteocel are cancellous bone, demineralized bone matrix (DBM) and viable MSCs native to the marrow rich bone. Found in human bone marrow, MSCs are fundamental regenerative cells in the body and promote tissue repair by modulating immune responses and protecting damaged tissue. MSCs are believed to help regulate the behavior of other bone marrow cells.

Alex Lukianov, Chairman and Chief Executive Officer, said, "This acquisition directly supports our strategy of complementing our product suite with innovative technologies. Osteocel provides our exclusive sales force with a unique stem cell-based bone graft that is synergistic with our Formagraft product and significantly enhances our biologics offering. This allows us to participate in the $1.5 bi
'/>"/>